Zhenzhong Bioengineering Company
About us | Our company’s production facilities exceed the Good Manufacturing Practice (GMP) standards set by the Chinese government. At the beginning of 1998 we were the first company in Nanjing to be awarded GMP status by the Chinese Drug Administration Bureau. From 2001, Zhenzhong introduced a new production line for its Lentinan For Injection capable of producing 1.2 million units per year, which, as early as May 2002, had already been awarded GMP enterprise status. At present, our company is investing in the production of a new line of tablets and capsules for the treatment of malignant tumours. Zhenzhong stands alone in having attained international standards recognition and possess unique intellectual property rights. Our company’s main product, Lentinan for Injection (a form of lyophilized powder) is an internationally recognized product. In comparison with to other Biological Response Modifiers (BRMs) , patient response to Lentinan for Injection is relatively good. Cancer patients using the product have seen a significant improvement in their immunity levels. As a result, Lentinan for Injection has become one of China’s main BRMs and in 1997 was awarded first prize for technological advancement by the Jiangsu Provincial Government. Our Liposome Encapsulated Taxol (Paclitaxel) for Injection improves on previous forms of Taxol cancer treatment by eliminating the need for polyoxyethylated castor oil and ethanol in the medical solution, thereby reducing the incidence of potentially fatal allergic reactions. Over the next few years, Zhenzhong is committed to continued investment and development of new products for the market. We have a dynamic and experienced sales and marketing team located in 25 representative offices around the country including Beijing, Shanghai, Tianjin, Guangzhou and Jinan. Furthermore, we have established close relationships with over 200 hospitals throughout China. We are currently in the process of establishing an international network to introduce our products to the rest of the world. |
---|---|
Industry Focus | Drugs & Medications, Bio-technology Products, Pharmaceutical Chemicals |
Business Type | Manufacturer |
Products/Services | Lentinan for Injection - a biological response modifier for the treatment of various cancers.- Liposome Encapsulated Taxol (Paclitaxel) for Injection.- Selegiline (in development) |
No. of Employees | 101 - 500 People |
Annual Sales Range(USD) | US$5 Million - US$10 Million |
Legal Representative(CEO) | Scott Willis |